Compare Public Storage (PSA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Recursion Pharmaceuticals Inc — how do they compare? Public Storage trades at $294.6 (market cap $55.59B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: Public Storage is far larger — about 29.9× Recursion Pharmaceuticals Inc's market cap, and Public Storage pays a 3.97% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PSA | RXRX | |
|---|---|---|
Market Cap | $55.59B | $1.86B |
Sector | Real Estate | Health |
52-Week High | $330.47 | $6.79 |
52-Week Low | $258.44 | $2.84 |
Enterprise Value | $69.86B | $1.38B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $301.6, down slightly by 0.14% today, with a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Recent developments include the completion of the Public Storage Canada acquisition and a C$400 million senior notes offering in Canada. Valuation ratios are elevated, with a P/E of 28.82 and P/S of 10.88, while profitability remains strong with a net income margin of 41.8%.
The outlook is mixed: strong fundamentals and dividend payments support the stock, but high valuation and bearish technicals pose risks. Analyst consensus is a 'Hold' with a price target of $334.13, suggesting modest upside. Key risks include execution of recent acquisitions and sensitivity to interest rate changes. Investors should weigh solid earnings performance against premium valuation.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
